Latest News
Oxcia receives EMA orphan designation for OXC-201 in idiopathic pulmonary fibrosis
27 August 2026 - Swedish clinical-stage biotech company Oxcia AB, which develops therapies targeting oxidative stress and DNA damage response pathways, announced on Thursday that the European Medicines Agency has made the decision to grant Orphan Dru...
ReviR Therapeutics' RTX-117 receives FDA Rare Pediatric Disease Designation for Charcot-Marie-Tooth disease
27 August 2026 - Clinical-stage biotechnology company ReviR Therapeutics announced on Wednesday that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to RTX-117, the company's investigational oral s...
Graviton BioScience reports positive trial results for GV101 in chronic Graft versus Host Disease
27 August 2026 - Clinical-stage biotechnology company Graviton BioScience Corporation announced on Wednesday the publication of peer-reviewed data from a multicentre Phase Ib/II multi-dose, open-label clinical trial evaluating the safety, tolerabilit...
Cizzle Bio presents CIZ1B biomarker blood test for lung cancer at Next Generation Dx Summit
27 August 2026 - Cizzle Bio Inc, a biotechnology company advancing biomarker blood tests for early cancer detection, announced on Wednesday its participation in the 18th Annual Next Generation Dx Summit in Washington, D.C.On Monday, Dr. Lary A. Robin...
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic GEA eligible for ZIIHERA
27 August 2026 - Swiss healthcare company Roche (SIX: RO, ROG; OTCQX: RHHBY) announced on Wednesday that it has received FDA approval for expanded use of its PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH DNA Probe Cocktail tests.These companion diagno...